Skip to main content

Advertisement

SpringerLink
Log in

Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Antibodies against mutated citrullinated vimentin (anti-MCV) are of a comparable diagnostic value in rheumatoid arthritis (RA) as antibodies targeting citrullinated peptides (anti-CCP). Anti-CCP are present in up to 15% of psoriatic arthritis (PsA) patients, while the prevalence of anti-MCV in PsA patients has been poorly investigated. The aim of the present study was to assess the prevalence and relevance of anti-MCV antibodies in PsA patients. The study included 56 PsA patients. Clinical features, disease activity, and functional ability were noted by an experienced rheumatologist. Serum samples of all patients were analyzed for anti-MCV and anti-CCP antibodies using enzyme-linked immunosorbent assay. Data on 92 patients with RA, 44 patients with other inflammatory rheumatic diseases, and 107 healthy controls from a previous study were used to compare the prevalence of anti-MCV antibodies in PsA patients. Anti-MCV antibodies were positive in only two out of 56 (3.6%) PsA patients, which was significantly lower compared to RA patients (63%). The anti-MCV level was moderately positive and borderline in one patient each. Both patients had asymmetric polyarthritis, dactylitis, moderate to high disease activity, and were anti-CCP and rheumatoid factor (RF) negative. There was no significant difference in anti-MCV levels according to clinical subtypes of PsA and no correlation of anti-MCV levels with anti-CCP, RF, disease activity variables, and functional ability indices. According to study results, anti-MCV antibodies can be detected in a very small proportion of PsA patients with polyarthritic disease and are primarily related to the polyarthritic pattern rather than the specific diagnosis of RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics. Ann Rheum Dis 64(Suppl):14–17

    Google Scholar 

  2. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis—an analysis of 220 patients. Q J Med 62:127–141

    CAS  PubMed  Google Scholar 

  3. Torre-Alonso JC, Rodrigues-Perez A, Arribas-Castrillom JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C (1991) Psoriatic arthritis (PA): a clinical immunologic and radiological study. Brit J Rheumatol 30:245–250

    Article  CAS  Google Scholar 

  4. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology Oxford 42:778–783

    Article  CAS  PubMed  Google Scholar 

  5. Riedmann JP, Munoz S, Kavanaugh A (2005) The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis—a systematic review. Clin Exp Rheumatol 23(Suppl. 39):S69–S76

    Google Scholar 

  6. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749

    Article  PubMed  Google Scholar 

  7. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BAW, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709–715

    Article  PubMed  Google Scholar 

  8. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ (2004) Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 350:17–34

    Article  CAS  PubMed  Google Scholar 

  9. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166(6):4177–4184

    CAS  PubMed  Google Scholar 

  10. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 44(11):1374–1382

    Article  CAS  PubMed  Google Scholar 

  11. Suzuki A, Yamad R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K (2005) Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys res Commun 333:418–426

    Article  CAS  PubMed  Google Scholar 

  12. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P et al (2005) Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7:R1421–R1429

    Article  CAS  PubMed  Google Scholar 

  13. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T et al (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6(2):R142–R150

    Article  CAS  PubMed  Google Scholar 

  14. Strelkov SV, Herrmann H, Aebi U (2003) Molecular architecture of intermediate filaments. Bioassays 25:243–251

    Article  CAS  Google Scholar 

  15. Bang H, Egerer K, Gauliard A, Lϋthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56(8):2503–2511

    Article  CAS  PubMed  Google Scholar 

  16. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8(4):R119

    Article  PubMed  Google Scholar 

  17. Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF et al (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658–1663

    CAS  PubMed  Google Scholar 

  18. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45

    Article  CAS  PubMed  Google Scholar 

  19. Poulsom H, Charles PJ (2008) Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clinic Rev Allerg Immunol 34:4–10

    Article  CAS  Google Scholar 

  20. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735

    Article  CAS  PubMed  Google Scholar 

  21. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielantset H et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62:127–132

    Article  CAS  PubMed  Google Scholar 

  22. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  23. Blackmore M, Gladman DD, Husted J, Long J, Farewell VT (1995) Measuring health status in psoriatic arthritis: the health assessment questionnaire and its modification. J Rheumatol 22:886–893

    CAS  PubMed  Google Scholar 

  24. Marks R, Barton SP, Shuttleworth D, Finlay AY (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125:235–240

    Article  CAS  PubMed  Google Scholar 

  25. Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157:238–244

    Article  CAS  PubMed  Google Scholar 

  26. Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 16:79

    Article  Google Scholar 

  27. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811–819

    PubMed  Google Scholar 

  28. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45

    Article  CAS  PubMed  Google Scholar 

  29. Vossenar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ et al (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63:373–381

    Article  Google Scholar 

  30. Brickmann K, Yazdani-Biuki BJ, Mϋller T, Graninger WB, Brezinschek HP (2006) Anti-mutated-citrullinated-vimentin antibodies (MCV) in psoriatic arthritis. (Abstract) Ann Rheum Dis 65(Suppl II):648

    Google Scholar 

  31. Fabien N, Olson NO, Goetz J, Johanet C, Escande A, Bardin N et al (2008) Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clinic Rev Allerg Immunol 34:40–44

    Article  CAS  Google Scholar 

  32. Alenius GM, Berglin E, Rantapää-Dahlqvist S (2006) Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65:398–400

    Article  CAS  PubMed  Google Scholar 

  33. Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23

    Article  CAS  PubMed  Google Scholar 

  34. Bogliolo L, Alpini C, Caporali R, Scirè CA, Moratti R, Montecucco C (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511–515

    CAS  PubMed  Google Scholar 

  35. Cruyssen BV, Hoffman IEA, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145–1149

    Article  Google Scholar 

  36. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778–783

    Article  CAS  PubMed  Google Scholar 

  37. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749

    Article  PubMed  Google Scholar 

  38. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386

    Article  PubMed  Google Scholar 

  39. Innala L, Kokkonen H, Eriksson C, Jiddell E, Berglin E, Rantapaa-Dahlqvist S (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1–7

    Google Scholar 

  40. Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089

    Article  CAS  PubMed  Google Scholar 

  41. Mikuls TR, O’Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50:3776–3782

    Article  CAS  PubMed  Google Scholar 

  42. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A et al (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58–62

    Article  CAS  PubMed  Google Scholar 

  43. Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M et al (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis. J Rheumatol 33:497–500

    CAS  PubMed  Google Scholar 

  44. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39

    Article  CAS  PubMed  Google Scholar 

  45. Alessandri C, Bombardieri M, Pap N, Cinquini M, Magrini L, Tincani A, Valesini G (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The paper has resulted from the work on the scientific project entitled “Psoriatic arthritis—epidemiology and risk factors of progression”, supported by the Ministry of Science, Education and Sports, Republic of Croatia (Project No. 134-0000000-3531).

Disclosures

None.

Author information

Authors and Affiliations

  1. University Department of Chemistry, Sestre Milosrdnice University Hospital, Vinogradska 29, 10000, Zagreb, Croatia

    Andrea Tesija-Kuna, Marijana Miler, Ines Vukasovic & Nada Vrkic

  2. University Department of Rheumatology, Physical Therapy and Rehabilitation Medicine, Sestre Milosrdnice University Hospital, Zagreb, Croatia

    Simeon Grazio

  3. University Department of Rheumatic Diseases and Rehabilitation, Zagreb University Hospital Center, Zagreb, Croatia

    Porin Peric

Authors
  1. Andrea Tesija-Kuna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simeon Grazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marijana Miler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ines Vukasovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Porin Peric
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nada Vrkic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Tesija-Kuna.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tesija-Kuna, A., Grazio, S., Miler, M. et al. Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clin Rheumatol 29, 487–493 (2010). https://doi.org/10.1007/s10067-009-1345-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1345-2

Keywords

Search

Navigation